|
|
 |
|
Viewing report
|
|
|
|
Innovations In Epigenetics: Advances in Technologies, Diagnostics & Therapeutics
Business Insights, Nov 2009, Pages: 165
The study of epigenetics - changes in gene expression that occur without a change in a cell’s DNA code – is becoming increasingly important as scientists explore how internal and external factors trigger cellular dysfunction and influence disease progression. Three main mechanisms - DNA methylation, histone modifications and changes in non-coding RNA - have been elucidated in epigenetics. Each in its own way may provide the industry with a greater understanding into the underlying mechanism of diseases, act as a potential source for biomarkers of disease and provide new targets for therapeutic intervention.
Besides everyday DNA analytical tools, epigenetic researchers have needed to adopt more complex technologies such as chromatin immunoprecipitation (ChIP) and DNA methylation methodologies as well as develop analytical tools to decipher the vast amount of epigenetic information. Advances in these technologies should enable epigenetic research to reduce cost and increase sample throughput making it more commercially attractive in the industry to discover biomarkers and validate novel epigenetic targets for diagnostic and pharmacological development.
Epigenetic medicine has arrived. The market is worth over $560 million derived from the sale of three anticancer products which target two epigenetic pathways - DNA methyltransferase (DNMT) and histone deacteylase (HDAC) – and around thirty epigenetic drugs are under development from more than a dozen biotechnology companies. These drugs focus mainly on the treatment of cancer, neurodegenerative and infectious diseases although research is underway to explore the role for epigenetics in cardiovascular, metabolic, ocular and other diseases. Whilst this market is still in its infancy KOLs believe it is on the cusp of a revolution, one which could change how patients are diagnosed and treated in the future.
Key features of this report
- Identify leading companies at the forefront of epigenetic research who will drive the market to develop a new generation of epigenetic therapies and diagnostics.
- Provide case studies of these leading companies developing epigenetic therapies to treat cancer, neurodegenerative and infectious diseases.
- Analyze the key trends and issues confronting the development of epigenetic therapies.
- Review the alliances, mergers, acquisitions and business strategies adopted by biotechs and big pharma to capitalize on the latest epigenetic developments.
Scope of this report
- Identify the companies leading the field in epigenetic research across a range of therapeutic areas
- Review their business strategies and the development of their epigenetic programs
- Learn more about the latest developments in epigenetic research and how non-coding RNAs may open up another Pandora's box for epigenetic research.
- Identify innovative pharmaceutical companies and discover the strategies they are adopting to tap into the epigenetic potential both as biomarkers of disease and targets for therapeutic intervention
Key Market Issues
- Declining industry productivity: It is a well documented fact that productivity in the pharma industry has declined during the past 15 years. The identification of new biomarkers of disease could aide the R&D process and support the preclinical and clinical development of small molecule therapeutics.
- Innovative new drug classes: The identification of underlying mechanisms of diseases could identify new target for small molecule therapeutic intervention that may be used alone or in combination with traditional therapies to extend their usage.
Key findings from this report
- New epigenetic therapies have entered the market. The first medicines were approved in 2006 for the treatment of cancer and a host of new small molecule therapies are now under development which are more selective and target different classes of chromatin modifying enzymes enabling a more targeted approach to treatment.
- The ability of innovative companies to generate intellectual property is a key driver for the sector as the market become more competitive in this new area of science. The unravelling of the human epigenome will be the first step in identifying new epigenetic markers which may have potential as biomarkers an area of considerable interest for the pharmaceutical industry at the present time.
Key questions answered
- Which companies are the market leaders in the epigenetics industry, identified through therapeutic areas (cancer, infectious diseases, neurodegenerative diseases, metabolic, cardiovascular, ophthalmic, other diseases) and recent alliances with the pharmaceutical companies?
- What are the key products of these companies and how do they exemplify the future direction of the epigenetic therapies?
- How is the pharmaceutical industry approaching the need for new targeted epigenetic therapies and what strategies are they taking?
Customers who bought this item also bought
Epigenetics Market Trends 2011
Biomarkers - Technologies, Markets and Companies
Epigenetics: Tools, Diagnostics, Drugs and World Market
Epigenetics - Global Strategic Business Report
DNA Sequencing - Technologies, Markets and Companies
RNAi - Technologies, Markets and Companies
Gene Therapy - Technologies, Markets and Companies
Biochips and Microarrays - Technologies, Markets and Companies
Epigenetics, Pluripotency, and Reprogramming 2009
Proteomics - Technologies, Markets and Companies
|
|
|
|
